Cited by 4,352Genomics and Phylogenetic StudiesGenomics and Rare DiseasesGenomic variations and chromosomal abnormalities

Coming of age: ten years of next-generation sequencing technologies

Open access
Goodwin, Sara, McPherson, John D., McCombie, W. Richard·2016·Nature Reviews Genetics

Abstract

Since the completion of the human genome project in 2003, extraordinary progress has been made in genome sequencing technologies, which has led to a decreased cost per megabase and an increase in the number and diversity of sequenced genomes. An astonishing complexity of genome architecture has been revealed, bringing these sequencing technologies to even greater advancements. Some approaches maximize the number of bases sequenced in the least amount of time, generating a wealth of data that can be used to understand increasingly complex phenotypes. Alternatively, other approaches now aim to sequence longer contiguous pieces of DNA, which are essential for resolving structurally complex regions. These and other strategies are providing researchers and clinicians a variety of tools to probe genomes in greater depth, leading to an enhanced understanding of how genome sequence variants underlie phenotype and disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrg.2016.49

Cites

133 of 133 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advances in various omics technologies have significantly improved understanding of CHO cells at different levels and enabled rational targeting of glycosylation effectors for improved biopharmaceutical production.

    “Advances in various omics technologies have significantly improved our understanding of CHO cells at different levels and enabled the rational targeting of glycosylation effectors for improved biopharmaceutical production [27,71,72,150–152].”

    From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [151]

    The Applications section describes how next-generation sequencing has improved genomic and transcriptomic research, supporting the broad point that these technologies deepen biological understanding. It does not address CHO cells, glycosylation effectors, or improved biopharmaceutical production; searches for CHO cells and Chinese hamster ovary glycosylation found no relevant passage. Page numbers were not available in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • Currently, readout of the DNA sequences needed for data decoding relies heavily on established DNA sequencing technologies, most prominently sequencing-by-synthesis (SBS) as commercialized by Illumina.

    “Currently, readout of the DNA sequences needed for data decoding relies heavily on established technologies for DNA sequencing in life science applications, most prominently sequencing-by-synthesis (SBS) as commercialized by Illumina.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 10

  1. [5]Veritas Genetics. Veritas genetics launches $999 whole genome and sets new standard for genetic testing — Press Release. Veritas Genetics [online], https://www.veritasgenetics.com/documents/VG-launches-999-whole-genome.pdf (updated 4 Mar 2016).
  2. [6]Veritas Genetics. Veritas genetics breaks $1,000 whole genome barrier — Press Release. Veritas Genetics [online], https://www.veritasgenetics.com/documents/VG-PGP-Announcement-Final.pdf (29 Sep 2015).
  3. [33]BGI. Revolocity Whole Genome Sequencing Service — Press Release. BGI [online], http://u70g92ptbyk941g21dd41fc4.wpengine.netdna-cdn.com/wp-content/uploads/2015/10/Global-WGSRevolocity-ENG-10-15.pdf (2015).
  4. [46]Qiagen. Oncology insights enabled by knowledge base-guided panel design and the seamless workflow of the GeneReader NGS system — Press Release. Qiagen [online], http://www.genereaderngs.com/PROM-9192-001_1100403_WP_GeneReader_NGS_0116_NA.pdf (2016).
  5. [72]Heger M 10X Genomics, Pacific Biosciences provide business updates at JP Morgan Healthcare Conference. GenomeWeb [online], https://www.genomeweb.com/sequencing-technology/10x-genomics-pacific-biosciences-provide-business-updates-jp-morgan-healthcare (13 Jan 2016).
  6. [106]Illumina. Illumina forms new company to enable early cancer detection via blood-based screening — Press Release. Illumina [online], http://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=2127903 (10 Jan 2016).
  7. [115]Karow J Oxford Nanopore presents details on new high-throughput sequencer, improvements to Minion. GenomeWeb [online], https://www.genomeweb.com/sequencing/oxford-nanopore-presents-details-new-high-throughput-sequencer-improvements-mini (16 Sep 2014).
  8. [117]Roche. Roche acquires Genia Technologies to strengthen next generation sequencing pipeline — Press Release. Roche [online], http://www.roche.com/media/store/releases/med-cor-2014-06-02.htm (2 Jun 2014).
  9. [118]Heger M Illumina unveils mini targeted sequencer, semiconductor sequencing project at JP Morgan Conference. GenomeWeb [online], https://www.genomeweb.com/sequencing-technology/illumina-unveils-mini-targeted-sequencer-semiconductor-sequencing-project-jp (1 Jan 2016).
  10. [119]NanoString. NanoString Technologies presents proof-of-concept data for novel massively parallel single molecule sequencing chemistry at AGBT meeting — Press Release. NanoString [online], http://investors.nanostring.com/releasedetail.cfm?ReleaseID=954517 (11 Feb 2016).

Cited by

Sorted by citations

Authors
Goodwin, S., McPherson, J. D., & McCombie, W. R.
Affiliations
  • Cold Spring Harbor Laboratory (US)
  • University of California System (US)
Corresponding author
McCombie, W. Richard
Venue
Nature Reviews Genetics
Published
2016-05-17
Volume
17
Issue
6
Pages
333-351
ISSN
  • 1471-0056 (ISSN-L)
  • 1471-0064
OpenAlex
W2396849069
Cited by
4,352
References
133
Citations by year
2026: 303 · 2025: 410 · 2024: 423 · 2023: 349 · 2022: 425 · 2021: 492 · 2020: 460 · 2019: 476 · 2018: 523 · 2017: 413 · 2016: 72 · 2015: 1 · 2014: 2
FWCI
44.83
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Genetics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
Funders
  • National Institutes of Health (5p30ca045508-35)
  • National Cancer Institute (P30-CA045508)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
Keywords
next-generation sequencing, short-read sequencing, long-read sequencing, DNA sequencing technologies, genome sequencing, sequencing cost, genome organization, structural variants
MeSH terms
Humans, Phenotype, Genetic Variation, Genome, Human, Genomics, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review